Treatment of Corneal Lesions in Individuals with Vernal Keratoconjunctivitis  by Kumagai, Naoki et al.
Treatment of Corneal Lesions in
Individuals with Vernal
Keratoconjunctivitis
Naoki Kumagai1, Ken Fukuda2, Youichiro Fujitsu1, Keisuke Seki2 and Teruo Nishida1
ABSTRACT
Vernal keratoconjunctivitis, a severe form of allergic conjunctival disease, is characterized by the development
of various types of corneal lesions in conjunction with proliferative changes in the conjunctiva. Expression of
bioactive substances, such as chemokines and adhesion molecules, by corneal fibroblasts likely contribute to
the formation of corneal lesions by promoting local infiltration, activation, and survival of immune cells. Prolif-
eration and deposition of extracellular matrix by conjunctival fibroblasts also may provide conditions which sup-
port the activation and survival of immune cells. Topical administration of corticosteroids is the principal mode
of treatment for conjunctival inflammation in individuals with vernal keratoconjunctivitis. In some individuals,
however, the surgical removal of conjunctival giant papillae or of corneal plaques is indicated.
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INTRODUCTION
CORNEAL LESIONS IN ALLERGIC CONJUNCTI-
VAL DISEASES
Allergic conjunctival diseases are induced by invasion
of antigens, such as those associated with tree pollen
or dead mites, into the conjunctival sac of sensitized
individuals. These diseases are classified into several
subtypes― including allergic conjunctivitis ( AC ) ,
atopic keratoconjunctivitis (AKC), vernal keratocon-
junctivitis (VKC), and giant papillary conjunctivitis
(GPC)―on the basis of the presence or absence of
conjunctival proliferative changes, atopic dermatitis,
and conjunctival foreign bodies such as contact
lenses, surgical sutures, or prostheses (Fig. 1).
In individuals with milder forms of allergic conjunc-
tival diseases, such as AC, the main symptoms in-
clude ocular itching , tearing , and watery eye dis-
charges. Vision in such individuals is not disturbed
because of a lack of corneal involvement. In contrast,
VKC is characterized by visual disturbances in addi-
tion to prominent ocular itching, discharge, pain, and
secondary ptosis. These symptoms are caused by se-
vere allergic inflammation of the conjunctiva and the
resulting development of corneal lesions. According
to a nationwide study of allergic conjunctival diseases
conducted by the Japanese Ophthalmologist Society,
more than 50% of individuals with VKC have corneal
lesions (Fig. 2a). 1 These lesions include superficial
punctate keratopathy , corneal erosions , persistent
corneal epithelial defects, corneal ulcers, and corneal
plaques (Fig. 2b―e). VKC is also characterized by the
presence of proliferative changes in the conjunctiva,
which manifest clinically as giant papillae on the up-
per tarsal conjunctiva and swelling of the corneal-
conjunctival limbic region．
The symptoms of most patients with AC can be
controlled by topical administration of antiallergy eye-
drops such as those containing mast cell stabilizers
or antihistamines. However, corneal lesions and con-
junctival proliferative changes in individuals with
VKC are often resistant to such therapy and remain a
challenge in the treatment of ocular allergy.
ALLERGOLOGICAL CHARACTERISTICS OF
THE OCULAR SURFACE
The ocular surface possesses a unique anatomic
structure and this structure may contribute to the
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Fig. 1　Classification of alergic conjunctival diseases. Alergic conjunctival diseases are classified as alergic conjunctivitis 
(AC), atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), and giant papilary conjunctivitis (GPC) on the basis of 
the presence or absence of conjunctival proliferative changes, atopic dermatitis, and conjunctival foreign bodies.
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specificity of ocular allergy. Allergic inflammation is
readily evoked in the tarsal and bulbar conjunctiva
given that (1) the conjunctiva has an extensive vascu-
lature, (2) immune cells, such as mast cells, lympho-
cytes, and eosinophils, are abundant in the normal as
well as the diseased conjunctiva,2-4 and (3) the con-
junctiva is a mucous tissue that is moistened by tear
fluid, which extracts antigens from dry particles of
tree pollen or dead mites. In contrast, primary aller-
gic reactions do not occur in the cornea because (1)
the cornea is an avascular tissue, (2) no immune cells
are present in the cornea , with the exception of
Langerhans’ cells at the periphery of the corneal epi-
thelium,5 and (3) the barrier function of corneal epi-
thelial cells prevents antigens from invading the cor-
neal stroma. Like the conjunctiva , the cornea is in
contact with a thin layer of tear fluid (Fig. 3). The cor-
nea is thus exposed to bioactive molecules―such as
histamine , 6 eosinophil-derived cytotoxic proteins , 7
leukotrienes,8 and proteinases9 that are released into
tear fluid as a result of allergic inflammation in the
conjunctiva. Exposure to such agents, especially to
eosinophil-derived cytotoxic proteins,10 can result in
damage to corneal epithelial cells. Corneal damage is
clinically more important than conjunctival changes
because of the prominent role of the cornea in vision.
ROLE OF RESIDENT CELLS OF THE CORNEA IN
THE PATHOGENESIS OF ALLERGIC CONJUNC-
TIVAL DISEASES
Expression of Chemokines by Resident Cells of
the Cornea
Resident cells of the cornea, such as epithelial cells
and fibroblasts, are not considered to contribute di-
rectly to the pathophysiology of ocular allergic reac-
tions. Rather, these cells are thought to be bystand-
ers or victims of such reactions, which are induced
and maintained by the activation of immune cells
such as mast cells , lymphocytes , and eosinophils .
However, recent studies have shown that these cor-
neal resident cells play an important role in the patho-
genesis of allergic conjunctival diseases.
Allergic conjunctival diseases are characterized pa-
thologically by the local infiltration of eosinophils, a
process that is triggered by the presence of the
chemokine eotaxin in the affected tissue.11 The con-
centration of eotaxin in tear fluid is increased in indi-
viduals with VKC, especially in those with corneal le-
sions.12 Eosinophils accumulate at the tips of giant pa-
pillae, which are located adjacent to the tear fluid and
the cornea. These giant papillae are characterized by
erosion of the overlying conjunctival epithelium
(Figs. 4a, b). The numbers of eosinophils in the con-
junctiva as well as in tear fluid and ocular discharge
are increased in individuals with VKC13 and most of
these cells are degranulated (Figs. 4c, d). The con-
centrations of the proinflammatory cytokine tumor
necrosis factor-α (TNF-α),14 T helper cell 2 (Th2) cy-
tokines interleukin (IL)-4,15 and IL-13 in tear fluid are
also increased in VKC patients．
We examined the effect of these cytokines on the
expression of eotaxin by corneal epithelial cells, cor-
neal fibroblasts , and conjunctival fibroblasts in cul-
ture. Corneal fibroblasts expressed a small amount of
eotaxin in response to stimulation with either TNF-α,
IL-4, or IL-13. However, the production of eotaxin by
these cells was increased synergistically by the com-
bination of TNF-α and either IL-4 or IL-13.16 In con-
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Fig. 2　Corneal lesions associated with alergic conjunctival diseases. (a) Preva-
lence of various types of corneal lesion in individuals with seasonal alergic conjunc-
tivitis (SAC), perennial alergic conjunctivitis (PAC), or vernal keratoconjunctivitis 
(VKC) in Japan. SPK, superficial punctate keratopathy. Modified with permission 
from reference 1. (b) Superficial punctate keratopathy revealed by fluorescein 
biostaining. (c) Proliferative lesion in the corneal-conjunctival limbic region. (d) Per-
sistent corneal epithelial defect. (e) Corneal plaque.
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trast, corneal epithelial cells did not express eotaxin
in response to stimulation with TNF-α, IL-4, or IL-13
or with combinations thereof. Conjunctival fibroblasts
produced eotaxin on exposure to these same cytoki-
nes , but the amount of chemokine synthesized by
these cells was much smaller than that produced by
corneal fibroblasts．
VKC, similar to allergic diseases in other organs, is
also characterized by the local infiltration of Th 2
cells,17 which is controlled mainly by the production
of thymus- and activation-regulated chemokine
(TARC)18 and macrophage-derived chemokine
(MDC).19 The regulation of TARC expression in cor-
neal cells is similar to that of eotaxin expression. Cul-
tured corneal fibroblasts thus do not express a detect-
able amount of TARC protein or mRNA in response
to stimulation with various individual cytokines, in-
cluding TNF-α , IL-4, and IL-13 ; exposure of these
cells to the combination of TNF-α and either IL-4 or
IL-13, however , results in the production of large
amounts of TARC.20 Corneal epithelial cells do not
express this chemokine in response to stimulation
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Fig. 3　Structure of the outer eye. The cornea and conjunc-
tiva are separated by a thin layer of tear fluid.
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with various cytokines alone or in combination ,
whereas cytokine-stimulated conjunctival fibroblasts
produce TARC in amounts much smaller than those
synthesized by corneal fibroblasts. MDC is not ex-
pressed by cultured corneal epithelial cells, corneal fi-
broblasts,21 or conjunctival fibroblasts. These various
observations indicate that corneal fibroblasts, but not
corneal epithelial cells, play an important role in the
local infiltration of eosinophils and Th2 cells by ex-
pressing the chemokines eotaxin and TARC.
Expression of Adhesion Molecules by Resident
Cells of the Cornea
Expression of adhesion molecules by resident cells
also contributes to the local infiltration and activation
of immune cells.22 The local accumulation of neutro-
phils is mediated predominantly by the interaction of
leukocyte function-associated antigen-1 (LFA-1) with
intercellular adhesion molecule-1 ( ICAM-1) , which
are expressed on the surface of neutrophils and resi-
dent cells, respectively. Similarly, the infiltration of
eosinophils and lymphocytes is mediated by the at-
tachment of very late antigen-4 (VLA-4) on the leuko-
cytes to vascular cell adhesion molecule-1 (VCAM-1)
on resident cells．
We examined the expression of ICAM-1 and
VCAM-1 and its regulation in cultured corneal cells.
Corneal epithelial cells expressed a constitutive level
of ICAM-1 on the cell surface and the abundance of
this adhesion molecule was increased by stimulation
of the cells with TNF-α.23 These cells did not express
VCAM-1, however, in the absence or presence of vari-
ous cytokines. Similar to corneal epithelial cells, cor-
neal fibroblasts expressed ICAM-1 at the cell surface
under basal conditions and the abundance of this ad-
hesion molecule was increased by cell stimulation
with TNF-α. Although these cells did not express a
constitutive level of VCAM-1, they produced small
amounts of this adhesion molecule in response to
stimulation with TNF-α, IL-4, or IL-13 and exhibited a
synergistic response to stimulation with TNF-α and
either IL-4 or IL-13. Given that specific infiltration of
eosinophils and lymphocytes, rather than that of neu-
trophils, is observed in the ocular region of individu-
als with VKC, these results indicate that corneal fibro-
blasts, rather than corneal epithelial cells, play an im-
portant role in ocular allergic reactions by expressing
VCAM-1 in response to cytokine stimulation．
Mechanism of Exacerbation of Ocular Allergic
Reactions
On the basis of our observations with cultured cor-
neal cells, we propose the following model for the ex-
acerbation of ocular allergic reactions : (1) Primary
allergic reactions are induced in the conjunctiva ,
where immune cells are abundant, (2) The concentra-
tions of bioactive substances , such as eosinophil-
derived cytotoxic proteins , proinflammatory cytoki-
nes, and Th2 cytokines, increase in the tear fluid, (3)
The corneal epithelium is damaged as a result of ex-
posure to these agents , especially the eosinophil-
derived cytotoxic proteins , found in tear fluid , (4 )
Corneal fibroblasts, which are located in the corneal
stroma , also come into contact with the bioactive
molecules as a result of the impaired barrier function
of the injured corneal epithelium, (5) Corneal fibro-
blasts activated by exposure to cytokines produce
chemokines and adhesion molecules, (6) Local infil-
tration of immune cells is triggered by the chemoki-
nes and adhesion molecules expressed by corneal fi-
broblasts, (7) The immune cells and corneal fibro-
blasts likely engage in mutual stimulation and
thereby promote inflammation and tissue destruc-
tion．
ROLE OF CONJUNCTIVAL FIBROBLASTS IN
THE PATHOGENESIS OF OCULAR ALLERGY
Individuals with corneal lesions associated with VKC
manifest prominent proliferative changes of the con-
junctiva, such as the development of giant papillae of
the upper tarsus and limbic lesions . Histological
analysis reveals that these changes are characterized
by the accumulation of immune cells, such as eosino-
phils, mast cells, and lymphocytes, as well as by an in-
crease in the number of conjunctival fibroblasts . 14
Deposition of extracellular matrix , including fi-
bronectin and collagen types I and III , is also in-
creased in giant papillae.14 Given that the concentra-
tions of various Th2 cytokines in tear fluid are in-
creased in individuals with VKC, 15,24 we examined
the effects of such cytokines on cell proliferation and
deposition of extracellular matrix by cultured con-
junctival fibroblasts . 25 Conjunctival fibroblasts ex-
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Fig. 4　Eosinophil infiltration in VKC. (a, b) Cross-section of a giant papila from 
an individual with VKC. The accumulation of eosinophils under a conjunctival 
epithelial erosion is revealed by Hansel staining. Panel b is a higher-magnification 
view of the upper part of the image in panel a. (c) Ocular discharge of an individual 
with VKC. Hansel staining reveals the presence of numerous degranulated 
eosinophils. (d) Electron microscopic image of eosinophils in the ocular discharge 
of an individual with VKC. Scale bars: 20 μm (a―c) or 1 μm (d).  
press receptors for IL-4 and IL-1325 and each of these
cytokines promoted both the proliferation of these
cells and deposition of extracellular matrix. Coculture
with conjunctival fibroblasts enhances the survival
and activation of immune cells such as eosinophils.26
The presence of extracellular matrix also promotes
the survival of immune cells. Giant papillae therefore
likely provide an environment that is conducive to the
activation of eosinophils and other immune cells.
TREATMENT OF VKC
Pharmacological Therapies
Pharmacological therapies, including those based on
mast cell stabilizers, antihistamines, and corticoster-
oids, constitute an important mode of treatment of
corneal lesions in individuals with VKC. Local admini-
stration of mast cell stabilizers or antihistamines
alone is usually not sufficient to suppress active aller-
gic inflammation in such patients , although these
drugs are the first choice for the treatment of AC.
However , these agents are routinely used because
their administration allows the dose of corticosteroid
to be reduced. The efficacies of oral antiallergy drugs
in individuals with VKC are not well characterized.
Corticosteroids play a central role in the treatment
of VKC patients , especially those with corneal le-
sions. These drugs are usually administered as eye-
drops , and , among which dexamethasone and be-
tamethasone are the most effective therapeutically
but also frequently associated with pronounced side
effects . Fluorometholone eyedrops are less effica-
cious but have fewer side effects ; they are thus not
usually sufficient to control conjunctival inflammation
or heal corneal lesions in individuals with VKC. Dex-
amethasone or betamethasone is therefore often
needed to treat VKC patients with corneal lesions.
The effects of these drugs should be monitored, how-
ever, by clinical imaging of the cornea and conjunc-
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Fig. 5　Efect of corticosteroid eyedrops on the conjunctival proliferative changes and persistent corneal epithelial defect in an 
individual with VKC. Top row, photographs of the upper tarsal conjunctiva; middle row, photographs of the cornea; botom row, 
fluorescein staining of the cornea, showing the corneal epithelial defect.
Before treatment 1 week 2 weeks
tiva. Effective treatment with corticosteroids is mani-
fest by the relatively rapid (within few days) resolu-
tion of conjunctival changes such as edema, hypere-
mia, and exudation. The giant papillae also gradually
decrease in size, but several months of treatment are
required for their complete disappearance (Fig. 5).
The area and density of superficial punctate keratopa-
thy and the area of corneal epithelial erosion are im-
portant measures for judging the effectiveness of cor-
ticosteroid therapy. Corneal plaques, once formed,
are not usually affected by corticosteroid treatment.
In the most severe cases of VKC, short-term admini-
stration of oral corticosteroids (for example, predni-
solone at a daily dose of 0.6 mg per kilogram of body
mass) is usually effective (Fig. 6). Subconjunctival or
subdermal injection of corticosteroids at the upper
tarsus should also be considered in the most severe
cases.
In general, corticosteroids have local as well as sys-
temic side effects . In the ocular region , treatment
with corticosteroids can result in steroid cataract ,
steroid glaucoma, or microbiological infection of the
cornea. The induction of steroid cataract differs little
among individuals and is closely related to the total
dose of corticosteroid administered. Steroid cataract
can thus be induced in virtually anyone by treatment
with corticosteroids in a dose dependent manner. In
contrast , the incidence of steroid glaucoma differs
markedly among individuals. Even small doses of cor-
ticosteroid can induce steroid glaucoma in so-called
“steroid responders ” . The development of steroid
glaucoma is related to the one-time dose, rather than
the total dose, of corticosteroid administered. Steroid
glaucoma is induced at a much greater frequency by
local administration of corticosteroid than by sys-
temic administration . Local administration of corti-
costeroids is also a risk factor for corneal infection．
Staphylococcus aureus and herpes simplex virus are
the major causes of corneal infection in individuals
with atopic dermatitis, which is often associated with
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Fig. 6　Efect of oral corticosteroid (prednisolone, 0.6 mg/kg per day) treatment on the corneal lesions of an individual with 
VKC. Left column, photographs of the upper tarsal conjunctiva; middle column, photographs of the cornea; right column, fluores-
cein staining of the cornea, showing the corneal epithelial defect.
Before treatment
1 week after treatment
VKC.
Surgical Therapies for Corneal Lesions in VKC
Surgical removal of giant papillae is indicated in indi-
viduals with VKC and corneal erosion, corneal ulcer,
or superficial punctate keratopathy covering the en-
tire cornea, even in those treated with frequent ad-
ministration of corticosteroid eyedrops. All giant pa-
pillae on the upper tarsal conjunctiva should be re-
moved mechanically using local anesthesia. Corneal
epithelial lesions usually diminish within several days
after surgery (Fig. 7). Although conjunctival papillae
gradually recur in most individuals several months af-
ter the operation, surgery is a rapid and reliable treat-
ment for severe corneal lesions associated with VKC.
Elimination of giant papillae relieves conjunctival in-
flammation, at least in part, through the removal of
conjunctival fibroblasts and extracellular matrix, the
consequent loss of the supportive environment for in-
flammatory cells, as well as through the removal of
the inflammatory cells themselves.
Corneal plaques form in individuals with VKC sub-
sequent to corneal ulceration or the persistent cor-
neal epithelial defects. Once formed, corneal plaques
persist for many months or years and their surface re-
mains unexposed by the corneal epithelium even if
conjunctival inflammation is well controlled. This is
possibly explained by the fact that corneal epithelial
cells cannot attach to or migrate on the debris of cor-
neal epithelial cells and eosinophils that constitutes
such plaques. The presence of corneal plaques thus
inhibits normal corneal epithelial healing and they
are usually removed surgically in order to promote
healing. Before treatment, however, conjunctival in-
flammation must be adequately controlled . We ad-
ministered eyedrops containing fibronectin isolated
from the patient’s own blood to facilitate healing of
the corneal epithelium after plaque removal (Fig. 8).
CONCLUSION
Treatment of ocular allergic reactions, including that
of corneal lesions in individuals with VKC, relies pre-
dominantly on the application of eyedrops containing
antiallergy drugs developed for systemic use . To
date, only corticosteroids, mast cell stabilizers, and
antihistamines are sold as eyedrops. The introduction
of other types of antiallergy drugs, such as leukot-
riene antagonists and inhibitors of immunoglobulin E
production, in eyedrop form will likely improve the
treatment options for individuals with allergic con-
junctival diseases.
Allergic conjunctival diseases exhibit pathophysi-
ological characteristics that are distinct from allergic
diseases of other organs. These characteristics are
closely associated with the function of resident cells
in the cornea and conjunctiva as well as with the anat-
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Fig. 7　Efect of resection of giant papilae on corneal lesions in an individual with 
VKC. Upper row, photographs of the upper tarsal conjunctiva; lower row, fluores-
cein staining of the outer eye, showing the corneal epithelial defect.
Before treatment 1 day after treatment
Fig. 8　Efect of corneal plaque removal and fibronectin eyedrops on corneal epithelial erosion in an individual with VKC. Upper
row, photographs of the cornea；lower row, fluorescein staining of the cornea, showing the corneal epithelial defect. LV, left vis-
ual acuity.
Before treatment 3 days after treatment 10 days after treatment
LV=(0.5) LV=(0.5) LV=(1.2)
omy of the cornea and conjunctiva and the physiologi-
cal properties of tear fluid. Future treatment of these
ophthalmic disorders should be directed at the regu-
lation of resident cells in the cornea and the conjunc-
tiva.
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